Background and Objective: Acinetobacter, has been identified as an important pathogen in nosocomial outbreaks with high levels of emerging drug resistance. The present study was conducted in Acinetobacter spp to find out the utility of the multiplex PCR assay, which may be used as a useful technique in the early detection & prevention of blaOXA-23 and blaOXA-58 gene harbouring in clinical isolates taken from the patients coming to a tertiary care hospital.
Material and Methods: Strains of Acinetobacter collected from different clinical samples were subjected to antimicrobial susceptibility testing. Strains which were found showing resistance to imipenem by both disk diffusion and minimum inhibitory concentration (MIC), were analysed for the presence blaOXA-23 and blaOXA-58 (CLASS D) by using multiplex PCR.
Results: Among 175 strains of Acinetobacter collected from the clinical samples, 45 strains showed imipenem resistance, both by disk diffusion and MIC out of which 19(42.2%) were positive for blaOXA-58 gene and all strains 45(100%) were positive for blaOXA-23 gene.
Conclusion: The present study shows that there is dissemination of genes produced carbapenem resistant in the Acinetobacter isolates. This scientific evidence can be used to limit the spread of such strains in hospital settings as well as in the community, and also may help in initiating specific hospital infection control measures.
Yamamoto M, Nagao M, Matsumura Y, Matsushima A, Ito Y, Takakura S, et al. Interspecies dissemination of a novel class 1 integron carrying blaIMP-19 among Acinetobacter species in Japan. J Antimicrob Chemother. 2011;66:2480-3.
Gur D, Korten V, Unal S, Deshpande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58) -producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol. 2008;57(Pt 12):1529-32.
Coelho J, Woodford N, Turton J, Livemore DM. Multiresistant Acinetobacter in the UK: how big a threat? J Hosp infect. 2004;58:167-9.
Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin infect Dis. 2006;42:692-9.
Weinstein A.A. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med. 1991;91(3B):179S-184S.
Rolain JM, Parola P, Cornaglia G, New Delhi metallo b-lactamase (NDM-1) towards a new pandemia Clin Microbial Infect. 2010;16:1699-701.
Pelag AY, Seifert H, Peterson DL. Acinetobacter baumannii emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-82.
Ofori-Asenso R. “When the Bug Cannot Be Killed”-The Rising Challenge of Antimicrobial Resistance. Medicines (Basel). 2017;4.pii: E40.
Kusradze Ia, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemases genes in multi-drug resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob. 2011;38:164-8.
Mugnier PD, Poirel L, Naas T, Nordmann P. World wide dissemination of the blaOXA-23 carbapenemases gene of Acinetobacter baumannii. Emerg infect Dis. 2010;16:35-40.
Karthikeyan K, Thirunarayan MA, Krishnan P Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumanni from India. J Antimicrobial Chemotherapy. 2010;65:2253-4.
Nemec, A., L. Janda, O. Melter, L. Dijkshoorn. Genotypic and phenotypic similarity of multiresistant Acinetobacter baumanni isolates in the Czech Republic. J. Med. Microbiol. 1999;48.287-96.
Woodford N, Ellington MJ, Coelho JM, Turton IF, Ward ME. Brown S, et al. Multiplex PCR for encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob. 2006;27:351-3.
Joshi PR, Acharya M, Kakshapati T, Leungtongkam U, Thummeepak R, Sitthisak S. Co-existence of blaOXA-23 and blaNDM-1 genes of Acinetobacter baumannii isolated from Nepal: antimicrobial resistance and clinical significance. Antimicrob Resist Infect Control. 2017;6:21.